Breast Cancer Research and Advancements-Sci Forschen

Aims and Scope

The Journal of Breast Cancer Research and Advancements encourages original research, expert review on Breast Cancer and Oncology at the forefront of experimental, clinical and translational studies. JBCRA commits to publishing the result of research and clinical practice; case reports interesting to an international audience of scientists and professionals dedicated medical advances across the broad spectrum of Breast Cancer Research.

The journal pursues contributions which prioritize excellence, novelty, applicability, clarity, focus and interest to the readership. Cancer researchers, Geneticists, Obstetric Surgeons, Clinical researchers and Oncology scientists are contributors of JBCRA articles.

JBCRA is peer-reviewed to assure the scientific value and clinical significance of its diverse content.

Call for submissions

The Journal of Breast Cancer Research and Advancements publishes articles of original, interdisciplinary and translational research. The Editor actively encourages Clinical aspects andknowledge of processes that contribute to breast cancer and its metastases and insights into cancer biology. Similarly, JBCRA is interested in trials that will have an impact on the understanding of mammary gland health and disease. Case reports, focused research on a broad range of disciplines as well as experimental papers may be submitted. Furthermore, authors may contribute short reviews (by invitation from the Editor) and letters to the editor.


Subjects covered by The Journal of Breast Cancer Research and Advancements
  • Surgical Oncology
  • Engineered Tissue Replacements
  • Tumor suppressor genes
  • Clinical cell-based therapies
  • Therapy and Rehabilitation
  • Cellular and molecular biology of cancer
  • Stem cell research
  • Molecular Imaging
  • Pathophysiology
  • Life Sciences
  • Regenerative Medicine
  • Breast tumor function
  • Biomedicine
  • Cell Biology
  • Growth regulatory genes
  • Cell cycle control
  • Apoptosis and necroptosis
  • Resistance to cancer therapies
  • Development of better methodologies to ameliorate prognosis